MK-5172: A second-generation protease inhibitor for the treatment of hepatitis C virus infection

Expert Opinion on Investigational Drugs

Volumn 23, Issue 5, 2014, Pages 719-728

  Gentile, Ivan ^a   Buonomo, Antonio Riccardo ^a   Borgia, Federico ^a,b   Zappulo, Emanuela ^a   Castaldo, Giuseppe ^a,b   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Hepatitis C virus; MK 5172; NS3; NS4; Protease inhibitors; Resistance

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; MK 5172; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; MK-5172; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE;

ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION; VIRAL CLEARANCE; VIRUS STRAIN; ANIMAL; CLINICAL TRIAL (TOPIC); ENZYMOLOGY; TREATMENT OUTCOME; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEPATITIS C; HUMANS; PROTEASE INHIBITORS; QUINOXALINES; TREATMENT OUTCOME;

EID: 84898441875     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.902049     Document Type: Article

References (87)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15
2. Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 2013;57:2117-23
3. Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009;46:222-9
4. Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013;56:206-12
5. Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007;40:110-15
6. Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-Alpha and chemotherapy in hepatitis C and colorectal cancer: A case report. In Vivo 2013;27:527-9
7. Bourlière M, Poordad F, Vrijens B, et al. High medication adherence in HCVinfected patients taking a triple-DAA regimen for 12 weeks. Hepatology 2013;58:740A
8. Mele A, Spada E, Sagliocca L, et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: Results from the hepatitis surveillance system in Italy. J Hepatol 2001;35:284-9
9. Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: Experience with high-dose interferon therapy. Minerva Urol Nefrol 2013;65:83-4
10. Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997;26:15S-20S
11. Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepat Mon 2013;13:e8352
12. Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013;20:517-23
13. Sagnelli E, Pisaturo M, Stanzione M, et al. Presentation, outcomes, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013;13:00466-7
14. Coppola N, Zampino R, Bellini G, et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2013;21:00687-3
15. Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001;47:1696-700
16. Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008;28:141-52
17. Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013;27:773-7
18. Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009;43:81-7
19. Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014;13:20-6
20. Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013;164:e305-12
21. Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with oncohaematological disease undergoing chemotherapy. Dig Liver Dis 2012;44:49-54
22. Fusco F, D'Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: A systematic review of the literature. Expert Opin Pharmacother 2013;14:2533-44
23. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: Updated criteria and assignment web resource. Hepatology 2013;1:318-27
24. Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013;19:2793-8
25. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010;52:778
26. Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-Term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53
27. Tsuda N, Yuki N, Mochizuki K, et al. Long-Term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004;74:406-13
28. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-Alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology 2007;45:579-87
29. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. J Hepatol 2007;47:484-91
30. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
31. Coppola N, Pisaturo M, Tonziello G, et al. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-Analysis. BMC Infect Dis 2012;12:1471-2334
32. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74
33. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-Alfa based therapy. J Hepatol 2011;54:887-93
34. Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-Alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013;20:35-40
35. Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylatedinterferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study. Liver Int 2009;29:248-52
36. Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts nonresponse to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-75
37. Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. J Clin Apher 2009;24:190-6
38. Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011;17:5184-90
39. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012;18:800-5
40. Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014;33:559-67
41. Coppola N, Pascalis SD, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013;58:748-50
42. Gentile I, Viola C, Borgia F, et al. Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-21
43. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
44. Gentile I, Carleo MA, Borgia F, et al. The efficacy and safety of telaprevir-A new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-9
45. Gentile I, Borgia F, Buonomo AR, et al. A novel promising therapeutic option against hepatitis C virus: An oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013;20:3733-42
46. Gentile I, Borgia F, Zappulo E, et al. Efficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: The Dawn of the a New Era. Rev Recent Clin Trials 2014;In press
47. Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
48. Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58:583-92
49. Gentile I, Borgia F, Coppola N, et al. Daclatasvir: The first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;In press
50. Gentile I, Buonomo AR, Borgia F, et al. Ledipasvir: A novel synthetic antiviral for the treatment of HCV Infection. Expert Opin Investig Drugs 2014;23:561-71
51. FDA approves new treatment for hepatitis C virus. Release FN. 2013. Available from: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm376449.htm [Last accessed 19 February 2014]
52. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. FDA. FDA press release. 2013. Available from: Http://www.fda.gov/ forconsumers/byaudience/forpatientadvocates/ucm377920.htm [Last accessed 17 January 2014]
53. European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. Agency EM. 2013. Available from: Http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2013/11/ WC500155469. pdf [Last accessed 1 February 2014]
54. Harper S, McCauley JA, Rudd MT, et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. Acs Med Chem Lett 2012;3:332-6
55. Kuethe J, Zhong YL, Yasuda N, et al. Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172. Org Lett 2013;15:4174-7
56. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus: World. J Gastroenterol 2007;13(43):5673-81
57. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56:4161-7
58. Shah U, Jayne C, Chackalamannil S, et al. Novel quinoline-based P2-P4 macrocyclic derivatives as pan-genotypic HCV NS3/4a protease inhibitors. ACS Med Chem Lett 2014;5:264-9
59. Brainard DM, Petry A, Anderson MS, et al. safety, tolerability, and pharmacokinetics ater single and multiple doses oF MK-5172, A novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in healthy subjects. Hepatology 2010;52:1216A-7A.
60. Caro L, Anderson M, Du L, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship for MK-5172, a novel hepatitis C virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 HCV-infected patients. Hepatology 2011;54:1005A-A
61. Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers. Hepatology 2013;58:437
62. Yeh WW, Caro L, Huang X, et al. No pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor MK-8742 in healthy volunteers. Hepatology 2013;58:438
63. Yeh WW, IP F, Bifano M, et al. Lack of pharmacokinetic interaction between HCV protease inhibitor MK-5172 and HCV NS5A inhibitor daclatasvir in healthy volunteers. Hepatology 2013;58:430-1
64. Talaty JE, Caro L, Yeh WW, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers. Hepatology 2013;58:445
65. Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers. Hepatology 2013;58:442-3
66. Caro L, Talaty JE, Guo Z, et al. Pharmacokinetic interaction between the HCV protease inhibitor MK-5172 and IV and oral rifampin in healthy volunteers. Hepatology 2013;58:446-7
67. Ludmerer S, Carroll S, McCauley J, et al. MK-5172, a novel macrocyclic inhibitor of NS3/4a protease demonstrates efficacy against viral resistance in the chimpanzee model of chronic hepatitis C virus infection. Antiviral Res 2010;86:A21-1
68. Petry AS, Fraser IP, O'Mara E, et al. Safety and antiviral activity of MK-5172, a next generation HCV N53/4A protease inhibitor with a broad HCV genotypic activity spectrum and potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2011;54:531A-A
69. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: A phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010;138:913-21
70. Manns MP, Bourliere M, Benhamou Y, et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011;54:1114-22
71. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
72. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009;10:181-9
73. Pasquinelli C, McPhee F, Eley T, et al. Single-And multiple-Ascending- dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 2012;56:1838-44
74. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002
75. Manns M, Vierling JM, Bacon BR, et al. High sustained viral response at 12-And 24-week follow-up of MK-5172 with pegylated interferon ALFA-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-cirrhotic patients. J Hepatol 2013;58:S30-0
76. Howe A, Ludmerer S, Liu R, et al. MK-5172 in combination with PEG-interferon/ribavirin demonstrates robust efficacy and a low rate of resistance-Associated virologic failure in treatment naive genotype 1 chronic HCV-infected patients. J Hepatol 2013;58:S487-S87
77. Vierling JM, Lagging M, Brown AS, et al. High efficacy at lower doses of MK-5172 25 mg and 50 mg daily for 12 weeks in HCV genotype (G) 1 treatment-naive non-cirrhotic patients. Hepatology 2013;58:757-8
78. Lawitz E, Vierling JM, Murillo A, et al. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742 +/-RBV for 12 weeks in HCV genotype 1 infected patients: The C-worthy study. Hepatology 2013;58:244-5
79. Gane EJ, Ben Ari Z, Mollison L, et al. Efficacy and safety of an interferon-free regimen of MK-5172 + ribavirin for 12 weeks or 24 weeks in treatment naive, non-cirrhotic subjects with HCV GT1 infection: The C-SPIRIT study. Hepatology 2013;58:748-9
80. Caro L, Du L, Huang S, et al. Relationship between transaminase levels and plasma pharmacokinetics following administration of MK-5172 with pegylated interferon ALFA-2B and ribavirin (PR) to HCV genotype (G) 1 treatment-naive patients. J Hepatol 2013;58:S328-S28
81. Graham D, Acosta A, Guo Z, et al. MK-5172, A second generation HCV NS3/4A protease inhibitor is active against common resistance associated variants (RAVS) and exhibits cross-genotype activity. Hepatology 2011;54:543A-A
82. Lahser F, Liu R, Bystol K, et al. A combination containing MK-5172 (HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons. Hepatology 2012;56:236A-A
83. Strizki JM, Barnard RJO, Cheney C, et al. Evaluation of ns3 amino acid variants in a phase 1b study of genotype 1 (GT1) and gt3 infected patients with the HCV protease inhibitor, MK-5172. J Hepatol 2012;56:S479-S79
84. Barnard RJ, Howe AY, Strizki JM, et al. No MK-5172 Resistance Associated Variants (RAVs) identified in a vanguard cohort of treatment-naive, genotype 1, non-cirrhotic patients enrolled in the MK-5172 phase 2B study. Hepatology 2012;56:719A-A
85. Borgia G, Carleo MA, Gaeta GB, et al. Hepatitis B in pregnancy. World J Gastroenterol 2012;18:4677-83
86. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012;56:1247-53
87. Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: Secondgeneration protease inhibitors. Liver Int 2013;33:80-4